The Medicines Management Programme (MMP) are involved in a number of initiatives relating to medical devices for glucose monitoring including continuous glucose monitoring (CGM) sensors and blood glucose test strips (BGTS).
Preferred Products
The Medicines Management Programme (MMP) identified preferred continuous glucose monitoring (CGM) sensors with associated systems in July 2024. This review was updated in August 2026.
The evaluation process was undertaken in accordance with the 2025 HSE-MMP roadmap for the identification of preferred continuous glucose monitoring sensor(s) with associated system(s).
The MMP has identified the following preferred CGM sensors for stand-alone use.
Preferred CGM sensors for stand-alone use
CGM sensor - Reimbursement code
- Freestyle Libre 2 Plus - 86901
- Freestyle Libre 2 (for existing users only) - 85581
- Dexcom ONE+ - 97636
- Accu-Chek SmartGuide - 97633
For people with diabetes who are insulin pump users, using the Mylife Ypsopump, the MMP has identified one preferred CGM sensor.
Preferred CGM sensor for use with Mylife Ypsopump
CGM sensor - Reimbursement code
- Freestyle Libre 3 Plus - 86903
The MMP identified preferred blood glucose test strips (BGTS) with associated meter(s) for adults with type 1 and type 2 diabetes mellitus in February 2021. This review was updated in December 2021, February 2023, March 2025 and July 2025.
The MMP has developed resources to support the prescribing of the preferred products, including a preferred CGM sensors poster and preferred BGTS poster, outlining notable features of these products and other useful information.
The posters and associated evaluation reports for preferred CGM sensors and preferred BGTS can be found below.
For further information, please contact mmp@hse.ie.
- MMP Evaluation Report Preferred CGM Sensors (PDF, 885 KB, 45 pages)
- MMP Poster for Preferred CGM Sensors (PDF, 322 KB, 2 pages)
- MMP Evaluation Report Preferred BGTS (PDF, 1.1 MB, 35 pages)
- MMP Poster for Preferred BGTS (PDF, 927 KB, 2 pages)
- Roadmap for the identification of preferred CGM sensor(s) with associated system(s) (PDF, 210 KB, 2 pages)
- Cover page for submissions (PDF, 183 KB, 1 page)
Reimbursement Application System for CGM sensors
The HSE has implemented a reimbursement application system for continuous glucose monitoring (CGM) sensors, with effect from 1 December 2023. From this date, all patients newly initiated on CGM sensors must receive prior approval for reimbursement support. Reimbursement support is available for patients with type 1 diabetes mellitus only.
The Medicines Management Programme (MMP) review reimbursement applications submitted by diabetes healthcare professionals on behalf of patients, seeking approval for reimbursement support of CGM sensors. Frequently Asked Questions for healthcare professionals and users of CGM are provided below.